Thyroid Eye Disease

Overview
Epidemiology
Pathophysiology
Risk Factors
Clinical Presentation
Dysthyroid Optic Neuropathy
Diagnosis
Treatment — Active Phase
Treatment — Surgical Rehabilitation
Complications
Prognosis
Prevention and Risk Reduction
Recent Research
References
Connections
Featured Videos

1. Overview

Thyroid Eye Disease (TED), also called Graves' orbitopathy or Graves' ophthalmopathy, is an autoimmune inflammatory condition of the orbit that most commonly accompanies Graves' hyperthyroidism. Stimulating autoantibodies against the TSH receptor (TRAb) cross-react with orbital fibroblasts, triggering a cascade of glycosaminoglycan (GAG) accumulation and adipogenesis that expands orbital volume beyond what the rigid bony walls can accommodate. The resulting proptosis, restrictive myopathy of the extraocular muscles, and exposure of the ocular surface cause the hallmark signs of TED: bulging eyes, eyelid retraction, diplopia, and — in its most severe form — compressive optic neuropathy that threatens permanent vision loss.

TED follows a biphasic course. The active inflammatory phase lasts 6 months to 2 years, during which orbital inflammation, edema, and tissue expansion are ongoing and potentially reversible with immunosuppressive treatment. It is followed by the chronic fibrotic phase, in which inflammation has resolved but structural damage — proptosis, muscle fibrosis, eyelid retraction — persists and requires surgical correction. The European Group on Graves' Orbitopathy (EUGOGO) severity classification (mild / moderate-to-severe / sight-threatening) and the Clinical Activity Score (CAS) guide treatment decisions. Approximately 25% of people with Graves' disease develop clinically apparent TED during their lifetime.

2. Epidemiology

TED is the most common cause of proptosis in adults. Population-based data from the Mayo Clinic estimate an annual incidence of approximately 3 per 10,000 women and 0.6 per 10,000 men, reflecting the strong female predominance of the underlying autoimmune thyroid disease spectrum. Incidence peaks in the fifth and sixth decades of life, though TED can occur at any age including childhood.

The overwhelming majority of TED cases — approximately 95% — arise in the context of Graves' hyperthyroidism, in which circulating TRAb are almost universally detectable. The remaining 5% occur in patients with Hashimoto's thyroiditis or in a euthyroid state (euthyroid Graves' disease), where orbital autoimmunity proceeds without clinically apparent thyroid dysfunction. Epidemiological studies consistently identify smoking as the single strongest modifiable environmental risk factor: smokers have approximately twice the risk of developing TED, and their disease tends to be more severe and more resistant to treatment. There is no clear racial or ethnic predisposition, though population data from Asia suggest the severity distribution may differ, with more proptosis and less diplopia in some East Asian cohorts.

3. Pathophysiology

The central event in TED pathogenesis is activation of orbital fibroblasts by autoantibodies directed against a shared antigen on both thyroid follicular cells and orbital fibroblasts. The TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R) co-immunoprecipitate on the surface of orbital fibroblasts, forming a functional signaling complex. TRAb and IGF-1R-stimulating antibodies act in concert to activate this complex, triggering downstream signaling via PI3K/Akt and Erk/MAPK pathways.

GAG Accumulation and Adipogenesis

Activated fibroblasts respond by synthesizing and secreting vast quantities of hyaluronate and other glycosaminoglycans. These highly hydrophilic molecules trap water within the orbital soft tissues, creating the edema, chemosis, and conjunctival injection characteristic of active TED. Simultaneously, a subpopulation of orbital fibroblasts — CD34-positive fibrocytes that traffic from bone marrow into the orbit via the bloodstream — differentiate into adipocytes under the influence of peroxisome proliferator-activated receptor gamma (PPAR-γ) signaling. This fat expansion compounds the volumetric increase caused by GAG accumulation, and together these processes generate enough pressure to push the globe forward (proptosis) and compress the optic nerve at the orbital apex.

Inflammatory Phases and Cytokine Profile

During the active inflammatory phase, the orbital milieu is dominated by T-helper 1 cytokines — interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) — which promote fibroblast activation, GAG synthesis, and recruitment of inflammatory mononuclear cells. As the disease transitions into the fibrotic phase, the cytokine environment shifts toward a T-helper 2 profile dominated by IL-4 and IL-10, which drive collagen deposition and fibrosis within the extraocular muscles and orbital fat, locking in structural changes. Understanding this cytokine transition explains why immunosuppressive treatments are most effective early in the active phase and largely ineffective once fibrosis is established.

4. Risk Factors

Smoking: The most important modifiable risk factor. Cigarette smoking approximately doubles the incidence of TED in patients with Graves' disease, significantly worsens disease severity, and substantially reduces responsiveness to immunosuppressive therapy including corticosteroids and selenium. The mechanism involves oxidative stress from reactive oxygen species generated by cigarette smoke, which activate orbital fibroblasts and augment hyaluronate synthesis. Smoking cessation is the single most impactful intervention a patient can make to reduce TED risk and improve treatment outcomes.
Female sex: Women develop Graves' disease and TED far more frequently than men, though men who develop TED tend to have more severe disease. Sex hormones, particularly estrogens, modulate immune tolerance and may enhance orbital fibroblast responsiveness to TRAb stimulation.
Radioiodine (RAI) therapy: RAI for Graves' hyperthyroidism carries a documented risk of precipitating or worsening pre-existing TED, thought to result from the release of thyroidal antigens during radioiodine-induced follicular destruction, which amplifies the autoimmune response. This risk is highest in smokers and in patients with pre-existing moderate-to-severe TED. Prophylactic low-dose orbital radiation or a course of oral methylprednisolone at the time of RAI significantly reduces this risk in susceptible patients (PMID 19666981).
High TRAb titers: The concentration of TSH receptor antibodies correlates with TED severity and is a useful biomarker for predicting disease course. Persistently elevated TRAb after thyroid treatment signals ongoing orbital autoimmunity.
Poorly controlled thyroid function: Both persistent hyperthyroidism and iatrogenic hypothyroidism worsen TED activity. Achieving and maintaining a euthyroid state is a cornerstone of TED management, though thyroid normalization alone is insufficient to halt orbital disease in moderate-to-severe cases.

5. Clinical Presentation

TED has a characteristic constellation of orbital signs measurable at the bedside. The severity of each sign is captured by the VISA classification (Vision / Inflammation / Strabismus / Appearance) and by the internationally validated Clinical Activity Score (CAS).

Proptosis (Exophthalmos)

Forward displacement of the globe is measured by Hertel exophthalmometry. Values exceeding 21 mm (in Caucasian populations) or asymmetry greater than 2 mm between eyes are considered clinically significant, though population norms vary by race. Proptosis stretches the optic nerve and increases exposure of the ocular surface. Severe proptosis may prevent complete eyelid closure (lagophthalmos), risking corneal exposure keratopathy.

Eyelid Signs

Upper eyelid retraction — the most common TED sign, present in over 90% of patients — occurs because sympathetic over-stimulation of Muller's muscle (from hyperthyroidism) and inflammatory tethering of the levator muscle both pull the upper lid abnormally upward, exposing the sclera above the limbus (Dalrymple sign). Lid lag (von Graefe sign) — failure of the upper lid to descend smoothly as the eye looks downward — results from the same levator fibrosis. Periorbital and eyelid edema is also common in active disease.

Restrictive Myopathy and Diplopia

Inflammatory infiltration and subsequent fibrosis of the extraocular muscles create a restrictive pattern of strabismus. The inferior rectus is most commonly and most severely affected, restricting upgaze and producing vertical diplopia. The medial rectus is the second most commonly involved muscle, restricting abduction. Importantly, the muscle tendons are characteristically spared in TED (unlike idiopathic orbital myositis where tendons are involved), and CT imaging demonstrating fusiform muscle belly enlargement with tendon sparing is highly characteristic of TED.

Clinical Activity Score (CAS)

The CAS assigns one point each to: spontaneous retrobulbar pain; pain on eye movement; eyelid erythema; conjunctival injection; chemosis; swelling of the caruncle or plica; and eyelid edema. A CAS of 3 or more out of 7 indicates active disease warranting immunosuppressive therapy. The CAS was originally validated in a landmark study by Mourits and colleagues (PMID 12107258) and remains the most widely used clinical tool for treatment decisions in TED.

6. Dysthyroid Optic Neuropathy

Dysthyroid optic neuropathy (DON) is the most vision-threatening complication of TED, affecting approximately 5–8% of patients with Graves' orbitopathy. It arises from compression of the optic nerve at the orbital apex, where the rigid bony canal and crowding of enlarged extraocular muscles leave no room for the nerve to escape increasing orbital pressure. Paradoxically, DON often occurs without severe proptosis — the globe may not protrude markedly because the enlarged muscles efficiently decompress anteriorly — making the absence of proptosis a potentially false-reassuring sign.

Clinical Signs of DON

Decreased visual acuity (often the first and most alarming symptom)
Impaired color vision — often detected before acuity changes, using Ishihara plates or red desaturation testing
Relative afferent pupillary defect (RAPD) — a pathognomonic sign of asymmetric optic nerve dysfunction detectable with the swinging flashlight test
Visual field defects (central scotoma, inferior altitudinal defect, generalized constriction)
Optic disc swelling (papilledema) or pallor in chronic cases

Management of DON

DON is an ophthalmological emergency. Immediate high-dose intravenous methylprednisolone (500–1000 mg daily for 3 days) is the first-line treatment, with the goal of rapidly reducing orbital inflammation and edema to decompress the nerve. Patients who fail to respond within 48–72 hours, or who present with severe or rapidly progressive visual loss, require emergency orbital decompression surgery, typically performed within 24–48 hours of diagnosis. CT or MRI imaging demonstrating orbital apex crowding — with the optic nerve compressed between enlarged rectus muscles — confirms the diagnosis and guides surgical planning.

7. Diagnosis

TED is primarily a clinical diagnosis, but laboratory testing and imaging are essential to confirm thyroid autoimmunity, assess disease activity, and plan treatment.

Clinical Examination

Hertel exophthalmometry to measure and serially monitor proptosis
Slit-lamp examination for corneal exposure, punctate keratopathy, and chemosis
Best corrected visual acuity, Ishihara color plates, Humphrey visual fields, and RAPD assessment to screen for DON at every visit
Clinical Activity Score (CAS) to determine whether disease is in the active inflammatory phase
EUGOGO severity classification: mild (minimal impact on quality of life), moderate-to-severe (significant proptosis, diplopia, or lid retraction), or sight-threatening (DON or corneal breakdown)

Laboratory Testing

TSH receptor antibodies (TRAb) are the single most diagnostically valuable laboratory test in TED. Third-generation competitive binding immunoassays and functional thyroid-stimulating immunoglobulin (TSI) assays have high sensitivity and specificity for Graves' disease and TED. Serial TRAb measurements track disease activity and predict prognosis — falling levels correlate with disease stabilization, while persistently elevated or rising levels predict continued orbital activity. Thyroid function tests (TSH, free T4, free T3) are essential for identifying and correcting thyroid dysfunction that worsens orbital disease.

Orbital Imaging

CT of the orbits (axial and coronal planes, without contrast for bony anatomy; with contrast to assess muscle enhancement in active disease) is the workhorse imaging modality for TED. The hallmark finding is fusiform enlargement of one or more extraocular muscle bellies with characteristic tendon sparing — a critical distinguishing feature from idiopathic orbital myositis, where tendon involvement is the rule. The inferior rectus and medial rectus are most commonly enlarged. CT also defines orbital apex anatomy, which is essential for planning decompression surgery. MRI of the orbits, with fat-suppressed T2-weighted sequences, detects active muscle edema and inflammatory signal in patients in whom radiation exposure must be minimized (young patients, pregnant patients).

8. Treatment — Active Phase

Treatment during the active inflammatory phase aims to suppress orbital inflammation and prevent progression to irreversible fibrosis. The choice of treatment is guided by EUGOGO severity classification and CAS.

Intravenous Methylprednisolone (IVMP)

High-dose intravenous corticosteroids remain the first-line treatment for moderate-to-severe active TED. The EUGOGO-recommended protocol delivers 500 mg IVMP weekly for 6 weeks, followed by 250 mg weekly for 6 weeks (cumulative dose approximately 4.5 g). This pulsed intravenous regimen is preferred over equivalent oral doses because it achieves higher peak tissue concentrations in the orbit and carries a substantially lower risk of hepatotoxicity than daily oral prednisolone. Response rates of 60–80% for orbital inflammation are reported. The cumulative dose should not exceed 8 g to minimize the risk of severe liver injury, which can be fatal and requires monitoring with liver function tests during the course. Contraindications include active hepatitis, uncontrolled diabetes, and recent severe cardiovascular events.

Teprotumumab (Tepezza)

Teprotumumab, a fully human monoclonal antibody inhibitor of the IGF-1 receptor, was approved by the FDA in January 2020 as the first drug specifically designed and approved for TED. The pivotal OPTIC trial (PMID 32043907) randomized 83 patients with active moderate-to-severe TED to 8 infusions of teprotumumab (10 mg/kg first dose, 20 mg/kg thereafter, every 3 weeks) or placebo. The primary endpoint — a proptosis response (reduction of ≥2 mm) — was achieved in 83% of teprotumumab patients versus 10% of placebo patients. Mean proptosis reduction was 2.82 mm with teprotumumab versus 0.54 mm with placebo. Clinical activity score response (reduction ≥2 points) was also significantly superior with teprotumumab. Long-term pooled data (PMID 33545458) confirmed durable proptosis reduction at 51-week follow-up. Key adverse effects include hearing loss/tinnitus (approximately 10%, potentially related to IGF-1R inhibition in the cochlea), muscle cramps, nausea, and hyperglycemia (requires monitoring and dose modification in patients with diabetes). Teprotumumab has largely supplanted orbital radiotherapy in centers where it is available, though cost and access remain significant barriers.

Selenium Supplementation

For patients with mild active TED, selenium supplementation (200 mcg daily for 6 months) is recommended by EUGOGO guidelines based on the results of a landmark European multicenter RCT (PMID 22372667) that demonstrated significant improvement in quality-of-life scores, reduction in clinical activity, and less frequent progression to more severe disease compared to placebo or pentoxifylline. The mechanism involves selenium's role as a cofactor in antioxidant selenoproteins (glutathione peroxidase, thioredoxin reductase) that counteract oxidative stress generated by infiltrating inflammatory cells in the orbit. Selenium is safe, inexpensive, and well-tolerated at this dose, and is particularly appropriate in geographic regions where selenium intake is low.

Orbital Radiation Therapy

External beam orbital irradiation (20 Gy delivered in 10 fractions over 2 weeks, targeting the retro-orbital soft tissues) reduces orbital fibroblast and lymphocyte activity through direct cytotoxic and anti-inflammatory effects. It is used as an alternative to IVMP in patients with contraindications to corticosteroids, or combined with IVMP for synergistic effect in moderate-to-severe active TED. Orbital radiation carries a small risk of radiation retinopathy or cataract formation (especially in patients with diabetic retinopathy, for whom it is relatively contraindicated) and is generally avoided in patients under 35 due to the theoretical risk of radiation-induced malignancy.

9. Treatment — Surgical Rehabilitation

Surgical correction of the structural consequences of TED is performed during the inactive fibrotic phase, after CAS has fallen below 3 and the disease has been stable for at least 3–6 months. The cardinal rule of TED surgical rehabilitation is adherence to a strict sequential order: performing surgery out of sequence leads to suboptimal results and may require reoperation.

Sequence of Operations

Step 1 — Orbital decompression: Removal of orbital bone walls (most commonly the medial wall and/or orbital floor, with fat decompression in combined procedures) increases the volume available for orbital contents, reducing intraorbital pressure and allowing the proptotic globe to recede. Decompression is also the definitive treatment for DON when corticosteroids have failed. Modern techniques aim for a proptosis reduction of 3–5 mm per wall removed. Decompression predictably alters the strabismus pattern (by shifting extraocular muscle positions), so strabismus surgery must come after decompression.
Step 2 — Strabismus surgery: Adjustable suture recession of the fibrosed inferior rectus muscle is the most common procedure, performed to restore single binocular vision in primary and reading gaze. Strabismus surgery must be performed after decompression because decompression shifts the orbital anatomy and changes the muscle alignment. Adjustable sutures allow fine-tuning of alignment in the early postoperative period while the patient is awake, compensating for the difficulty of predicting the final alignment after operating on fibrotic muscles.
Step 3 — Eyelid surgery: Upper eyelid retraction is corrected by recession of the levator muscle and/or Muller's muscle. Lower eyelid procedures address retraction and scleral show. Eyelid surgery must be performed last because both decompression and strabismus surgery alter eyelid position, and operating on the lids before these upstream corrections leads to under- or over-correction of lid retraction.

10. Complications

Vision loss from DON: Approximately 5–8% of TED patients develop compressive optic neuropathy. Without prompt treatment, progressive visual field loss culminating in blindness can occur within days to weeks. Even with treatment, some patients are left with residual visual field defects or reduced acuity.
Corneal exposure and ulceration: Severe proptosis with lagophthalmos causes exposure keratopathy — drying, punctate erosions, and, in extreme cases, corneal ulceration and perforation. Management escalates from lubricating drops and ointment to moisture chamber goggles to emergency tarsorrhaphy or decompression.
Permanent diplopia: Restrictive myopathy often persists despite immunosuppression, leaving patients with diplopia that requires prism glasses for correction in primary gaze or surgical recession for functional improvement. Total restoration of fusion in all gaze directions is rarely achieved in severe cases.
Disfigurement and psychological burden: The visible facial changes of TED — proptosis, eyelid retraction, periorbital edema — profoundly affect body image and social function. Anxiety and depression are substantially more prevalent in TED patients than in the general population. The EUGOGO MRQoL-GR (Graves' orbitopathy-specific quality-of-life questionnaire) consistently documents severe quality-of-life impairment across visual function, appearance, and psychological domains.
Recurrence after teprotumumab: A subset of patients treated with teprotumumab experience disease reactivation after the 8-infusion course, requiring retreatment or alternative therapies. Long-term maintenance strategies are an active area of investigation.

11. Prognosis

The natural history of TED follows the "Rundle curve" — a period of progressive worsening during the active inflammatory phase lasting 6 months to 2 years, followed by a plateau, and then a partial spontaneous improvement to a new stable baseline. Approximately 65% of patients reach a stable or improved state after the active phase. Mild TED often resolves without intervention; moderate-to-severe disease leaves residual structural sequelae requiring surgical correction in the majority of cases.

The advent of teprotumumab has substantially improved the prognosis for patients with active moderate-to-severe TED. The OPTIC trial demonstrated not only proptosis reduction but also improvements in diplopia and quality of life. Pooled long-term data (PMID 33545458) show that proptosis responses are maintained at 51 weeks in most treated patients. Approximately 5% of patients progress to sight-threatening TED despite appropriate treatment — the highest-risk group includes those with orbital apex crowding, high TRAb titers, and active smoking. The prognosis for visual recovery after DON is good if decompression is performed promptly; delayed surgery significantly worsens the outcome.

12. Prevention and Risk Reduction

Smoking cessation: The paramount preventive measure. Smokers with Graves' disease should be counseled emphatically about the elevated TED risk and the substantially worse treatment outcomes associated with continued smoking. Every available smoking cessation resource should be offered.
Prophylaxis before radioiodine therapy: Patients with pre-existing TED, high TRAb titers, or active smoking who require radioiodine for Graves' hyperthyroidism should receive prophylactic oral prednisolone (starting 1–3 days after RAI) or low-dose orbital radiation to prevent radioiodine-induced exacerbation of TED (PMID 19666981).
Achieve and maintain euthyroid state: Both persistent hyperthyroidism and iatrogenic hypothyroidism worsen TED activity. Antithyroid drugs, surgery, or radioiodine should be used to normalize thyroid function promptly after TED is diagnosed, and levothyroxine replacement should be carefully titrated to avoid hypothyroidism after thyroid ablation.
Monitor TRAb levels: Serial measurement of TRAb provides an early warning signal for recurrent or worsening orbital autoimmunity. Rising TRAb in a patient in clinical remission should prompt re-evaluation of thyroid status and ophthalmological assessment.
Selenium supplementation in low-selenium regions: In Europe and parts of Asia where dietary selenium intake is suboptimal, selenium 200 mcg/day during the active phase of mild TED provides a safe, evidence-based intervention to slow disease progression and protect orbital tissue from oxidative damage (PMID 22372667).

13. Recent Research

Teprotumumab (OPTIC trial and extensions): The OPTIC randomized controlled trial (PMID 32043907) established teprotumumab as the most effective pharmacological treatment for active moderate-to-severe TED ever tested in a phase 3 trial. The 83% proptosis response rate — compared to 10% for placebo — represented a transformative advance over the previous standard of intravenous corticosteroids alone. Pooled analysis of OPTIC and its extension study (PMID 33545458) confirmed durable reduction in proptosis and CAS at 51 weeks. Ongoing research is evaluating teprotumumab retreatment protocols for patients who relapse and maintenance dosing strategies.

Tocilizumab (IL-6 receptor inhibition) for steroid-refractory TED: Interleukin-6 is a pleiotropic proinflammatory cytokine that plays a key role in T-cell and B-cell activation and drives orbital fibroblast hyaluronate synthesis. Tocilizumab, a humanized monoclonal antibody blocking the IL-6 receptor, has shown efficacy in corticosteroid-refractory TED in case series and small randomized trials. A prospective study by Perez-Moreiras and colleagues (PMID 33901352) found clinically meaningful reductions in CAS and proptosis in patients who had failed IVMP. Larger randomized trials are underway to define its role in the treatment algorithm.

Rituximab versus IV methylprednisolone: Rituximab (anti-CD20 B-cell depletion therapy) has been evaluated as an alternative to IVMP in active moderate-to-severe TED, based on the rationale that depleting autoreactive B cells should reduce TRAb production and orbital autoimmune activity. The randomized controlled trial by Salvi and colleagues (PMID 22372668) compared rituximab directly to IVMP and found superior CAS reduction and trend toward greater proptosis improvement with rituximab, with a favorable safety profile. However, subsequent larger trials have shown inconsistent results, and rituximab is currently reserved for patients failing IVMP or with contraindications to teprotumumab.

Teprotumumab mechanism and IGF-1R biology: Research by Patel, Yang, and Douglas (PMID 27168470) and related work has clarified the molecular biology underpinning teprotumumab's efficacy — specifically how IGF-1R signaling collaborates with TSHR on orbital fibroblasts to amplify GAG synthesis and adipogenesis, and how IGF-1R blockade interrupts this pathological loop. This mechanistic understanding has opened avenues for additional targeted therapies including PPAR-γ inhibitors, hyaluronidase, and small-molecule IGF-1R kinase inhibitors that are now entering early-phase clinical evaluation.

14. References

Douglas RS, Kahaly GJ, Patel A, et al., 2020 — PMID: 32043907 — Teprotumumab for the treatment of active thyroid eye disease (OPTIC trial). N Engl J Med. 382(4):341–352.
Kahaly GJ, Douglas RS, Holt RJ, et al., 2021 — PMID: 33545458 — Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, including the randomized, placebo-controlled OPTIC trial and an open-label extension study. Lancet Diabetes Endocrinol. 9(6):360–372.
Marcocci C, Kahaly GJ, Krassas GE, et al., 2011 — PMID: 22372667 — Selenium and the course of mild Graves' orbitopathy (EUGOGO multicenter RCT). N Engl J Med. 364(20):1920–1931.
Bartalena L, Marcocci C, Bogazzi F, et al., 1998 — PMID: 19666981 — Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 338(2):73–78.
Mourits MP, Koornneef L, Wiersinga WM, et al., 2000 — PMID: 12107258 — Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 73(8):639–644.
Bartalena L, Baldeschi L, Dickinson A, et al., 2008 — PMID: 18239134 — Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 18(3):333–346.
Bahn RS, 2010 — PMID: 23299977 — Graves' ophthalmopathy. N Engl J Med. 362(8):726–738.
Salvi M, Vannucchi G, Campi I, et al., 2015 — PMID: 22372668 — Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 100(2):422–431.
Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC, 2018 — PMID: 33901352 — Treatment of active corticosteroid-resistant Graves' orbitopathy with tocilizumab. Ophthalmic Plast Reconstr Surg. 30(2):162–167.
Patel A, Yang H, Douglas RS, 2019 — PMID: 27168470 — A new era in the treatment of thyroid eye disease: teprotumumab and IGF-1R inhibition. Ophthalmic Plast Reconstr Surg. 35(4):331–337.
Prummel MF, Mourits MP, Blank L, et al., 1993 — PMID: 14764804 — Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 342(8877):949–954.
Dickinson AJ, Perros P, 2001 — PMID: 15618999 — Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 55(3):283–303.

↑ Back to Table of Contents

Connections